The FDA has long been criticized for lapses in inspections of overseas manufacturing in China and India, which are the two major producers of drugs and raw ingredients for medicines.
The move highlighted the potential risks that firms involved in due diligence face in China as Xi Jinping has tightened the ruling Communist Party’s grip on information.
The technology needed to meet pending SEC climate disclosure rules on emissions is not want-to-have but is must-have, says Josh Bouk, president of Trax Technologies.